Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Absorption, metabolism and excretion of pyrazinamide in man.

Literature DB >> 5788407

Absorption, metabolism and excretion of pyrazinamide in man.

G A Ellard.

Abstract

Entities: Chemical Species

Mesh：

Substances：
Pyrazinamide

Year: 1969 PMID： 5788407 DOI： 10.1016/0041-3879(69)90020-8

Source DB: PubMed Journal: Tubercle ISSN： 0041-3879

Keyword Cloud
Cited

× No keyword cloud information.

25 in total

1. The management of tuberculous meningitis.

Authors: M Humphries
Journal: Thorax Date: 1992-08 Impact factor: 9.139

Review 2. An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.

Authors: Jotam Pasipanodya; Tawanda Gumbo
Journal: Antimicrob Agents Chemother Date: 2010-10-11 Impact factor: 5.191

3. Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients.

Authors: Justin J Wilkins; Grant Langdon; Helen McIlleron; Goonaseelan Colin Pillai; Peter J Smith; Ulrika S H Simonsson
Journal: Eur J Clin Pharmacol Date: 2006-05-10 Impact factor: 2.953

Review 4. Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm.

Authors: Sumit Chakraborty; Kyu Y Rhee
Journal: Cold Spring Harb Perspect Med Date: 2015-04-15 Impact factor: 6.915

5. Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used.

Authors: Jotam G Pasipanodya; Tawanda Gumbo
Journal: Antimicrob Agents Chemother Date: 2010-05-03 Impact factor: 5.191

Absorption, metabolism and excretion of pyrazinamide in man.

1. The management of tuberculous meningitis.

Review 2. An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.

3. Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients.

Review 4. Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm.

5. Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used.

Review 6. Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management.

7. Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects.

Review 8. Clinical pharmacokinetic considerations in the treatment of patients with leprosy.

9. Pyrazinoate excretion in the chimpanzee. Relation to urate disposition and the actions of uricosuric drugs.

10. Pyrazinamide blood concentrations in children suffering from tuberculosis: a comparative study at two doses.